Gene · 10419
Papers3,714
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 3,714
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers. | J Med Chem | 2025 | 40146197 | PubTator, text mining | PubMed |
| Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data. | ESMO Open | 2025 | 40138743 | PubTator, text mining | PubMed |
| PRMT5 attenuates regorafenib-induced DNA damage in hepatocellular carcinoma cells through symmetric dimethylation of RPL14. | J Gastrointest Oncol | 2025 | 40115921 | PubTator, text mining | PubMed |
| High PRMT5 levels, maintained by KEAP1 inhibition, drive chemoresistance in high-grade serous ovarian cancer. | J Clin Invest | 2025 | 40091834 | PubTator, text mining | PubMed |
| Alternative Splicing Analysis Reveals Adrenergic Signaling as a Novel Target for Protein Arginine Methyltransferase 5 (PRMT5) in the Heart. | Int J Mol Sci | 2025 | 40076920 | PubTator, text mining | PubMed |
| Design, synthesis and evaluation of pyrimidinobenzylamide and pyrimidinothiophenamide derivatives as inhibitors of DOT1L and related epigenetic targets DNMT3a, PRMT4 and other HMTs. | RSC Med Chem | 2025 | 40061000 | PubTator, text mining | PubMed |
| Specific sDMA modifications on the RGG/RG motif of METTL14 regulate its function in AML. | Cell Commun Signal | 2025 | 40057764 | PubTator, text mining | PubMed |
| PRMT5 highly expressed on CD16 + CD56- natural killer cells is correlated with NK cells exhaustion in colorectal cancer mesenchyme. | Cancer Immunol Immunother | 2025 | 40056169 | PubTator, text mining | PubMed |
| Tumor-intrinsic PRMT5 upregulates FGL1 via methylating TCF12 to inhibit CD8+ T-cell-mediated antitumor immunity in liver cancer. | Acta Pharm Sin B | 2025 | 40041915 | PubTator, text mining | PubMed |
| Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion. | J Med Chem | 2025 | 40035511 | PubTator, text mining | PubMed |
| PRMT5-mediated arginine methylation stabilizes GPX4 to suppress ferroptosis in cancer. | Nat Cell Biol | 2025 | 40033101 | PubTator, text mining | PubMed |
| Aberrant miRNA expression and protein arginine methyltransferase 5 (PRMT5) in cancer: A review. | Biochim Biophys Acta Mol Cell Res | 2025 | 39993609 | PubTator, text mining | PubMed |
| PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomide. | Res Sq | 2025 | 39989968 | PubTator, text mining | PubMed |
| CircPRMT5, a Potential Salivary Biomarker, Facilitates the Progression of Head and Neck Squamous Cell Carcinoma via the IGF2BP3-SERPINE1 Pathway. | Int J Nanomedicine | 2025 | 39931528 | PubTator, text mining | PubMed |
| MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design. | J Med Chem | 2025 | 39919252 | PubTator, text mining | PubMed |
| Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates. | Eur J Med Chem | 2025 | 39908794 | PubTator, text mining | PubMed |
| Dexmedetomidine plays a protective role in sepsis-associated myocardial injury by repressing PRMT5-mediated ferroptosis. | Toxicol Res (Camb) | 2025 | 39902345 | PubTator, text mining | PubMed |
| PRMT5 Maintains Homeostasis of the Intestinal Epithelium by Modulating Cell Proliferation and Survival. | Adv Sci (Weinh) | 2025 | 39899687 | PubTator, text mining | PubMed |
| PRMT5 Inhibition Enhances Therapeutic Efficacy of Cisplatin via Mediating miR-29b-3p-Mcl-1 Expression in Lung Adenocarcinoma. | Cell Biol Int | 2025 | 39891587 | PubTator, text mining | PubMed |
| In silico protein structural analysis of PRMT5 and RUVBL1 mutations arising in human cancers. | Cancer Genet | 2025 | 39874873 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10419/papers?page=17